Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study.

Adolescent Adult Aged Autoantibodies / blood Child Humans Longitudinal Studies Middle Aged Myelin-Oligodendrocyte Glycoprotein / immunology Optic Neuritis / blood Retina / diagnostic imaging Tomography, Optical Coherence Young Adult
Myelin-oligodendrocyte-glycoprotein Optic neuritis Optical coherence tomography

Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
25 Jul 2019
Historique:
received: 13 11 2018
accepted: 13 06 2019
entrez: 27 7 2019
pubmed: 28 7 2019
medline: 6 2 2020
Statut: epublish

Résumé

Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients. We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0-2.2) and 56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group's eyes included 18 eyes without (Eye At baseline in Eye We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by progressive GCIP reduction. This effect could be caused by a small number of Eye

Sections du résumé

BACKGROUND BACKGROUND
Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients.
METHODS METHODS
We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0-2.2) and 56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group's eyes included 18 eyes without (Eye
RESULTS RESULTS
At baseline in Eye
CONCLUSIONS CONCLUSIONS
We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by progressive GCIP reduction. This effect could be caused by a small number of Eye

Identifiants

DOI: 10.1186/s12974-019-1521-5 PMID: 31345223 PMC: PMC6657100
pubmed: 31345223
doi: 10.1186/s12974-019-1521-5
pii: 10.1186/s12974-019-1521-5
pmc: PMC6657100
doi:

Substances chimiques

Autoantibodies 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

154

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : Exc 257
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB TR128
Organisme : Guthy-Jackson Charitable Foundation
ID : NN
Organisme : National Multiple Sclerosis Society
ID : NN
Organisme : Friedrich-Baur-Stiftung
ID : NN
Organisme : Novartis Pharma
ID : NN
Organisme : Verein zur Therapieforschung für MS Kranke
ID : NN

Références

J Neuroinflammation. 2011 Dec 28;8:184
pubmed: 22204662
PLoS One. 2013 Aug 06;8(8):e71145
pubmed: 23940706
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
Neurology. 2014 Jul 1;83(1):73-7
pubmed: 24857925
Mult Scler. 2015 Feb;21(2):163-70
pubmed: 24948688
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40
pubmed: 25364774
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62
pubmed: 25635259
Mult Scler. 2015 May;21(6):678-88
pubmed: 25662342
J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):446-8
pubmed: 25749692
Ann Clin Transl Neurol. 2015 Mar;2(3):295-301
pubmed: 25815356
BMJ Open. 2015 Apr 02;5(4):e007766
pubmed: 25838512
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Mult Scler. 2016 Apr;22(4):470-82
pubmed: 26163068
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135
pubmed: 26236761
Lancet Neurol. 2016 Feb;15(2):198-209
pubmed: 26724103
Mult Scler. 2016 Oct;22(12):1541-1549
pubmed: 26869529
J Neuroimmunol. 2016 Apr 15;293:28-33
pubmed: 27049558
J Neurol. 2016 Jul;263(7):1323-31
pubmed: 27142714
Neurology. 2016 Jun 14;86(24):2303-9
pubmed: 27225223
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
J Neuroinflammation. 2016 Oct 20;13(1):275
pubmed: 27765056
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neuroinflammation. 2016 Nov 1;13(1):282
pubmed: 27802824
J Neurol. 2017 Jan;264(1):139-151
pubmed: 27844165
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 16;4(2):e322
pubmed: 28105459
Neurol Neuroimmunol Neuroinflamm. 2017 Feb 22;4(3):e334
pubmed: 28255575
Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335
pubmed: 28331892
Front Immunol. 2017 May 08;8:529
pubmed: 28533781
Neurol Neuroimmunol Neuroinflamm. 2017 Oct 27;5(1):e412
pubmed: 29114566
JAMA Neurol. 2018 Jan 1;75(1):65-71
pubmed: 29131884
EPMA J. 2017 Dec 22;9(1):21-33
pubmed: 29515685
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 13;5(3):e449
pubmed: 29552598
Front Neurol. 2018 Apr 04;9:217
pubmed: 29670575
Neurology. 2018 May 22;90(21):e1858-e1869
pubmed: 29695592
Ophthalmology. 2018 Oct;125(10):1628-1637
pubmed: 29716788
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1259-1265
pubmed: 29921610
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
Mult Scler Relat Disord. 2018 Oct;25:66-72
pubmed: 30048919
Front Neurol. 2018 Oct 23;9:888
pubmed: 30405519
Mult Scler. 2018 Nov 26;:1352458518815596
pubmed: 30475082

Auteurs

Frederike C Oertel (FC)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Olivier Outteryck (O)

Department of Neurology and Neuroradiology, Roger Salengro Hospital, University of Lille, INSERM 1171, Avenue du Professeur Emile Laine, 59037, Lille, France.

Benjamin Knier (B)

Department of Neurology, Klinikum Rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, Munich, Germany.

Hanna Zimmermann (H)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Nadja Borisow (N)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Judith Bellmann-Strobl (J)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Astrid Blaschek (A)

Department of Pediatric Neurology and Developmental Medicine, Dr. von Hauner's Children's Hospital, University of Munich, Lindwurmstraße 4, 80337, Munich, Germany.

Sven Jarius (S)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Markus Reindl (M)

Clinical Department of Neurology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.

Klemens Ruprecht (K)

Department of Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin, Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Edgar Meinl (E)

Institute of Clinical Neuroimmunology, Ludwig-Maximilians University, Marchioninistr. 15, 81377, Munich, Germany.

Reinhard Hohlfeld (R)

Munich Cluster for Systems Neurology, Feodor-Lynen-Str 17, 81377, Munich, Germany.
Institute of Clinical Neuroimmunology, Ludwig-Maximilians University, Marchioninistr. 15, 81377, Munich, Germany.

Friedemann Paul (F)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.
Department of Neurology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin, Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Alexander U Brandt (AU)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Robert-Rössle-Straße 10, 13125, Berlin, Germany. alexander.brandt@charite.de.
NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany. alexander.brandt@charite.de.
Department of Neurology, University of California Irvine, 30, 101 The City Dr S, Orange, CA, 92868, USA. alexander.brandt@charite.de.
ORCID: 0000-0002-9768-014X

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, Ludwig-Maximilians University, Marchioninistr. 15, 81377, Munich, Germany.

Joachim Havla (J)

Institute of Clinical Neuroimmunology, Ludwig-Maximilians University, Marchioninistr. 15, 81377, Munich, Germany.
Data Integration for Future Medicine consortium (DIFUTURE), Ludwig-Maximilians University, Marchioninistr. 15, Munich, 81377, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Optical coherence tomography in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Optical coherence tomography in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Optical coherence tomography in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Optical coherence tomography in...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Optical coherence tomography in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Optical coherence tomography in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Optical coherence tomography in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Optical coherence tomography in...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Autoantigènes › Glycoprotéine MOG › Optical coherence tomography in...
questionsmedicales.fr › Maladies de l'oeil › Atteintes du nerf optique › Névrite optique › Optical coherence tomography in...
questionsmedicales.fr › Organes des sens › Oeil › Rétine › Optical coherence tomography in...
questionsmedicales.fr › Techniques d'investigation › Imagerie optique › Tomographie optique › Tomographie par cohérence optique › Optical coherence tomography in...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Optical coherence tomography in...